Eulav Asset Management Intercept Pharmaceuticals, Inc. Transaction History

Eulav Asset Management

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$11.61 - $16.11 $2.32 Million - $3.22 Million	-200,000 Reduced 50.63%	195,000 $2.41 Million
Q2 2022 Jul 22, 2022	SELL	$11.23 - $19.59 $617,650 - $1.08 Million	-55,000 Reduced 12.22%	395,000 $5.46 Million
Q4 2021 Feb 11, 2022	SELL	$14.28 - $19.53 $3 Million - $4.1 Million	-210,000 Reduced 31.82%	450,000 $7.33 Million
Q3 2021 Nov 15, 2021	BUY	$12.99 - $20.47 $4.22 Million - $6.65 Million	325,000 Added 97.01%	660,000 $9.8 Million
Q4 2020 Feb 16, 2021	BUY	$24.48 - $42.47 $4.5 Million - $7.81 Million	184,000 Added 121.85%	335,000 $8.28 Million
Q1 2020 Apr 27, 2020	SELL	$48.35 - $118.68 $773,600 - $1.9 Million	-16,000 Reduced 9.58%	151,000 $9.51 Million
Q4 2019 Feb 13, 2020	SELL	$57.36 - $124.1 $1.72 Million - $3.72 Million	-30,000 Reduced 15.23%	167,000 $20.7 Million
Q2 2019 Aug 05, 2019	BUY	$77.77 - $120.68 $1.32 Million - $2.05 Million	17,000 Added 9.44%	197,000 $15.7 Million
Q1 2019 May 13, 2019	BUY	$91.83 - $120.68 $9.83 Million - $12.9 Million	107,000 Added 146.58%	180,000 $20.1 Million
Q4 2018 Feb 14, 2019	SELL	$85.79 - $126.46 $171,580 - $252,920	-2,000 Reduced 2.67%	73,000 $7.36 Million
Q3 2018 Oct 26, 2018	SELL	$88.49 - $127.55 $442,450 - $637,750	-5,000 Reduced 6.25%	75,000 $9.48 Million
Q1 2018 May 09, 2018	BUY	$52.72 - $67.25 $738,080 - $941,500	14,000 Added 21.21%	80,000 $4.92 Million
Q3 2017 Nov 14, 2017	BUY	$57.01 - $118.75 $798,140 - $1.66 Million	14,000 Added 26.92%	66,000 $3.83 Million
Q2 2017 Aug 14, 2017	BUY	N/A	52,000	52,000 $6.3 Million

1.04M

30K

5.9K

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

Get notified when there are updates to the investment portfolio of Eulav Asset Management, based on Form 13F filings with the SEC.

Stay updated on Eulav Asset Management with notifications on news.